

**Cefadroxil Monohydrate Formulation**

Version 2.1      Revision Date: 30.09.2023      SDS Number: 10679100-00005      Date of last issue: 04.04.2023  
Date of first issue: 06.05.2022

---

**SECTION 1: IDENTIFICATION**

Product name : Cefadroxil Monohydrate Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : 91-105 Harpin Street  
Bendigo 3550, Victoria Australia

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Respiratory sensitisation : Category 1

**GHS label elements**

Hazard pictograms :



Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary statements :

**Prevention:**

P261 Avoid breathing dust.

P284 Wear respiratory protection.

**Response:**

P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.

**Disposal:**

P501 Dispose of contents/ container to an approved waste

## Cefadroxil Monohydrate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	10679100-00005	Date of first issue: 06.05.2022

disposal plant.

### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.  
 Contact with dust can cause mechanical irritation or drying of the skin.  
 May form explosive dust-air mixture during processing, handling or other means.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 30 -< 60
Cefadroxil	66592-87-8	>= 30 -< 60
Magnesium stearate	557-04-0	< 10

### SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
 If not breathing, give artificial respiration.  
 If breathing is difficult, give oxygen.  
 Get medical attention.

In case of skin contact : Wash with water and soap.  
 Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.  
 Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention if symptoms occur.  
 Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
 Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).  
 Contact with dust can cause mechanical irritation or drying of the skin.

Protection of first-aiders : Dust contact with the eyes can lead to mechanical irritation.  
 First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

## Cefadroxil Monohydrate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	10679100-00005	Date of first issue: 06.05.2022

---

		Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire-fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Sodium oxides Nitrogen oxides (NO <sub>x</sub> ) Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## Cefadroxil Monohydrate Formulation

Version 2.1      Revision Date: 30.09.2023      SDS Number: 10679100-00005      Date of last issue: 04.04.2023  
 Date of first issue: 06.05.2022

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
 Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Avoid breathing dust.  
 Do not swallow.  
 Avoid contact with eyes.  
 Avoid prolonged or repeated contact with skin.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Keep container tightly closed.  
 Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.  
 Minimize dust generation and accumulation.  
 Keep container closed when not in use.  
 Keep away from heat and sources of ignition.  
 Take precautionary measures against static discharges.  
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
 When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.  
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.  
 Keep tightly closed.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	AU OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH

## Cefadroxil Monohydrate Formulation

Version 2.1      Revision Date: 30.09.2023      SDS Number: 10679100-00005      Date of last issue: 04.04.2023  
 Date of first issue: 06.05.2022

Cefadroxil	66592-87-8	TWA	500 mcg/m3 (OEB 2)	Internal
Further information: RSEN				
Magnesium stearate	557-04-0	TWA	10 mg/m3	AU OEL
		TWA (Inhalable particulate matter)	10 mg/m3	ACGIH
		TWA (Respirable particulate matter)	3 mg/m3	ACGIH

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection : Chemical-resistant gloves

Material

Eye protection : Wear safety glasses with side shields or goggles.  
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : powder

Colour : white

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	10679100-00005	Date of first issue: 06.05.2022

---

Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	10679100-00005	Date of first issue: 06.05.2022

---

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--

**Acute toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

**Cefadroxil:**

Acute oral toxicity	:	LD50 (Rat): > 8,000 mg/kg  LD50 (Mouse): > 7,000 mg/kg
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 6,000 mg/kg Application Route: Intraperitoneal  LD50 (Mouse): > 7,000 mg/kg Application Route: Intraperitoneal  LD50 (Rat): > 1,000 mg/kg Application Route: Intravenous  LD50 (Mouse): > 1,500 mg/kg Application Route: Intravenous

**Magnesium stearate:**

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

---

**Cefadroxil Monohydrate Formulation**

Version 2.1      Revision Date: 30.09.2023      SDS Number: 10679100-00005      Date of last issue: 04.04.2023  
Date of first issue: 06.05.2022

---

Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:****Cefadroxil:**

Result : Sensitiser

**Magnesium stearate:**

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**



**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	10679100-00005	Date of first issue: 06.05.2022

---

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion

**Cefadroxil Monohydrate Formulation**

Version 2.1      Revision Date: 30.09.2023      SDS Number: 10679100-00005      Date of last issue: 04.04.2023  
Date of first issue: 06.05.2022

---

Result: negative

**Cefadroxil:**

Effects on fertility : Test Type: Fertility  
Species: Mouse  
Application Route: Intraperitoneal  
Fertility: NOAEL: 400 mg/kg body weight  
Result: No adverse effects

Effects on foetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 500 mg/kg body weight  
Result: No adverse effects

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Cellulose:**

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Cefadroxil:**

Species : Mouse  
NOAEL : 200 mg/kg  
Application Route : Oral

## Cefadroxil Monohydrate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	10679100-00005	Date of first issue: 06.05.2022

---

Exposure time : 14 W  
 Target Organs : Prostate, male reproductive organs, Liver, Adrenal gland

Species : Rat  
 NOAEL : 100 mg/kg  
 Application Route : Oral  
 Exposure time : 26 W  
 Target Organs : Kidney

Species : Rat  
 LOAEL : > 316 mg/kg  
 Application Route : Oral  
 Exposure time : 26 W  
 Target Organs : Kidney

Species : Dog  
 LOAEL : 200 mg/kg  
 Exposure time : 26 W  
 Target Organs : Blood, Liver  
 Remarks : May cause damage to organs.

**Magnesium stearate:**

Species : Rat  
 NOAEL : > 100 mg/kg  
 Application Route : Ingestion  
 Exposure time : 90 Days  
 Remarks : Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Cefadroxil:**

Inhalation : Symptoms: Nausea, Vomiting, vaginitis, Headache, Dizziness, dry mouth, Fatigue, constipation, colitis, Gastrointestinal disturbance

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
 Exposure time: 48 h  
 Remarks: Based on data from similar materials

**Cefadroxil Monohydrate Formulation**

Version 2.1      Revision Date: 30.09.2023      SDS Number: 10679100-00005      Date of last issue: 04.04.2023  
Date of first issue: 06.05.2022

---

**Cefadroxil:****Ecotoxicology Assessment**

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

**Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	10679100-00005	Date of first issue: 06.05.2022

---

**Bioaccumulative potential****Components:****Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: &gt; 4

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable

**IATA-DGR**

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

**IMDG-Code**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable

**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	10679100-00005	Date of first issue: 06.05.2022

---

Labels : Not applicable  
EmS Code : Not applicable  
Marine pollutant : Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations****ADG**

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Hazchem Code : Not applicable

**Special precautions for user**

Not applicable

---

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

**The components of this product are reported in the following inventories:**

AICS : not determined  
DSL : not determined  
IECSC : not determined

---

**SECTION 16: ANY OTHER RELEVANT INFORMATION****Further information**

Revision Date : 30.09.2023  
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>  
Date format : dd.mm.yyyy

**Full text of other abbreviations**

**Cefadroxil Monohydrate Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	10679100-00005	Date of first issue: 06.05.2022

---

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.

ACGIH / TWA : 8-hour, time-weighted average  
AU OEL / TWA : Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN